CAM
KZR

Cormorant Asset Management’s Kezar Life Sciences KZR Stock Holding History

Cormorant Asset Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-120,000
Closed -$9.92M – 78
2022
Q2 		$9.92M Buy
+120,000
New +$10.6M 0.75% 41
2020
Q4 		– Sell
-93,180
Closed -$4.51M – 109
2020
Q3 		$4.51M Sell
93,180
-36,820
-28% -$1.76M 0.17% 77
2020
Q2 		$6.73M Buy
+130,000
New +$6.56M 0.26% 66
2019
Q4 		– Sell
-92,787
Closed -$3.04M – 75
2019
Q3 		$3.04M Sell
92,787
-4,042
-4% -$195K 0.19% 63
2019
Q2 		$7.47M Sell
96,829
-33,171
-26% -$5.16M 0.43% 56
2019
Q1 		$23.1M Sell
130,000
-12,291
-9% -$2.42M 1.56% 25
2018
Q4 		$33.6M Sell
142,291
-13,000
-8% -$3.18M 2.73% 11
2018
Q3 		$33.2M Sell
155,291
-2,000
-1% -$349K 2.16% 18
2018
Q2 		$27.2M Buy
+157,291
New +$27.4M 2.01% 18

Other funds holding KZR

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Cormorant Asset Management's KZR Position: Q3 2022 in Review

Cormorant Asset Management sold out of Kezar Life Sciences (KZR) in Q3 2022, closing a stake of 120,000 shares — an estimated $9.92M sold.

Cormorant Asset Management first reported a position in KZR in Q2 2018 and held it in 9 quarters. The position peaked at $33.6M in Q4 2018. 132 funds tracked by Wall St. Rank hold KZR as of Q3 2022.

  • Cormorant Asset Management reported no remaining Kezar Life Sciences position as of Q3 2022 after selling out during the quarter.
  • Cormorant Asset Management sold 120,000 Kezar Life Sciences shares in Q3 2022, an estimated $9.92M.
  • Cormorant Asset Management first reported a position in Kezar Life Sciences in Q2 2018 and held it in 9 quarters.
  • Cormorant Asset Management's Kezar Life Sciences position peaked at $33.6M in Q4 2018.
  • 132 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2022.

Based on Cormorant Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.